GlassScriptPhysician profile
James A Mcbride
NPI 1891057923
$233,605.01
in general payments reported to CMS, 2019-2025
55 companies · $73K in 2025
The $73K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $7,388 · 2021: $8,565 · 2022: $26K · 2023: $37K · 2024: $79K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $118K · Consulting Fee: $48K · Travel and Lodging: $15K · Food and Beverage: $8,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $118,030.00 |
| Consulting Fee | $48,347.50 |
| Travel and Lodging | $15,319.31 |
| Food and Beverage | $8,588.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $191,721.73 | 2019-2025 | Ams 700 Cxr Rte Kit, Advance Xp, General - Erectile Dysfunction |
| Endo USA, INC. | $23,516.55 | 2024-2025 | Xiaflex, Aveed |
| Endo Pharmaceuticals INC. | $13,185.18 | 2019-2024 | Xiaflex, Aveed, Edex |
| Coloplast Corp | $839.90 | 2019-2024 | Saffron |
| Astellas Pharma US INC | $530.66 | 2019-2025 | Xtandi |
| Antares Pharma, INC. | $367.58 | 2021-2025 | Xyosted, Tlando |
| Abbvie INC. | $346.22 | 2019-2025 | |
| Janssen Biotech, INC. | $331.52 | 2021-2025 | Erleada, Akeega |
| Pfizer INC. | $214.79 | 2020-2025 | |
| Ferring Pharmaceuticals INC. | $196.68 | 2024-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $176.82 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $167.24 | 2020-2025 | Welireg, Keytruda, Lynparza |
| Dendreon Pharmaceuticals LLC | $166.62 | 2019-2025 | Provenge |
| 180 Medical, INC. | $147.10 | 2019-2024 | |
| Myriad Genetic Laboratories, INC. | $136.64 | 2023 | Prolaris, Myrisk |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.